DERM
Journey Medical Corp
$6.00
+0.50%
$165.2M
No data for this timeframe.
Vol
Market Cap$165.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders7 funds
Inst. Value$8.5M
Inst. Activity3 buys / 1 sells
Reddit Sentiment67° Warm
SEC Reports2
Press Releases3
Recent Activity
May 19, 2026
other
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation
May 13, 2026
SEC
Journey Medical reported Q1 2026 revenue of $16.0M (+21% YoY) and a GAAP net loss of $(0.08) per share, narrowing from $
8-K — Impact 6/10
May 6, 2026
SEC
Journey Medical announced it will release Q1 2026 financial results on May 13, 2026, after market close. The press relea
PRESS-RELEASE — Impact 2/10
Apr 22, 2026
Insider
Maraoui Claude sold 49,277 shares
President & CEO @ $0.00 ($0.00)
Apr 22, 2026
Insider
Maraoui Claude sold 82,915 shares
President & CEO @ $0.00 ($0.00)
Apr 22, 2026
Insider
Benesch Joseph sold 28,907 shares
CFO @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
26,500 shares ($204.3K)
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
15,748 shares ($121.4K)
Price Targets
$13.50
+118.4% upside
Strong Buy
Current $6.18
Low $12.00
Median $13.00
High $16.00
4 analysts
$12.00
$16.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.02 ▼ -12.5% | $-0.07 — $0.06 | 86% YoY | 4 |
| Next Q | $0.05 ▼ -4.5% | $0.01 — $0.14 | 158% YoY | 4 |
| Current FY | $0.07 ▼ -10.3% | $-0.05 — $0.40 | 114% YoY | 4 |
| Next FY | $1.04 ▲ +2.0% | $0.45 — $1.76 | 1496% YoY | 4 |
Latest Reports
BULLISH
8-K
6/10
Journey Medical reported Q1 2026 revenue of $16.0M (+21% YoY) and a GAAP net loss of $(0.08) per share, narrowing from $
May 13, 2026
NEUTRAL
PRESS-RELEASE
2/10
Journey Medical announced it will release Q1 2026 financial results on May 13, 2026, after market close. The press relea
May 6, 2026
BULLISH
Press
6/10
Journey Medical Corporation announced that approximately 85% of commercial lives in the U.S. now have access to its rosa
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.9M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $1.9M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $273.8K | NEW |
| MORGAN STANLEY | $204.3K | ADD |
| WELLS FARGO & COMPANY/MN | $121.4K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 22, 2026 | Maraoui Claude | A | $0.00 |
| Apr 22, 2026 | Maraoui Claude | A | $0.00 |
| Apr 22, 2026 | Benesch Joseph | A | $0.00 |
| Apr 22, 2026 | Benesch Joseph | A | $0.00 |
| Apr 22, 2026 | Alloush Ramsey | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $8.5M total value (1,096,903 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 764,147 | $5.9M | 69.7% | ADD +51.8% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 244,000 | $1.9M | 22.2% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 35,507 | $273.8K | 3.2% | NEW |
| 4 | MORGAN STANLEY | 26,500 | $204.3K | 2.4% | ADD +27.8% |
| 5 | WELLS FARGO & COMPANY/MN | 15,748 | $121.4K | 1.4% | DOUBLED +109.1% |
| 6 | BANK OF AMERICA CORP /DE/ | 10,805 | $83.3K | 1.0% | TRIM -49.8% |
| 7 | FMR LLC | 196 | $1.5K | 0.0% | DOUBLED +931.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 20,732 | 26,500 | +27.8% | $204.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 7,533 | 15,748 | +109.1% | $121.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 21,537 | 10,805 | -49.8% | $83.3K | 2025-Q4 |
| FMR LLC | DOUBLED | 19 | 196 | +931.6% | $1.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,134 | 21,537 | +421.0% | $153.3K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 51,914 | 20,732 | -60.1% | $147.6K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 372,261 | 564,988 | +51.8% | $4.1M | 2025-Q2 |
| UBS Group AG | DOUBLED | 17,038 | 158,751 | +831.7% | $1.1M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 14,193 | 51,914 | +265.8% | $372.7K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 30,451 | — | $218.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 6,273 | — | $45.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 86 | 4,134 | +4707.0% | $29.7K | 2025-Q2 |
| MORGAN STANLEY | ADD | 9,700 | 14,193 | +46.3% | $83.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 44,568 | — | $174.3K | 2024-Q4 |
| UBS Group AG | NEW | — | 22,363 | — | $87.4K | 2024-Q4 |
| MORGAN STANLEY | NEW | — | 9,700 | — | $37.9K | 2024-Q4 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Maraoui Claude | President & CEO | A | 49,277 | $0.00 | $0.00 |
| Apr 22, 2026 | Maraoui Claude | President & CEO | A | 82,915 | $0.00 | $0.00 |
| Apr 22, 2026 | Benesch Joseph | CFO | A | 28,907 | $0.00 | $0.00 |
| Apr 22, 2026 | Benesch Joseph | CFO | A | 41,860 | $0.00 | $0.00 |
| Apr 22, 2026 | Alloush Ramsey | Chief Operating Officer | A | 46,863 | $0.00 | $0.00 |
| Apr 22, 2026 | Alloush Ramsey | Chief Operating Officer | A | 62,795 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
BULLISH
6/10
Journey Medical Corporation announced that approximately 85% of commercial lives in the U.S. now hav
Apr 21, 2026
BULLISH
7/10
Journey Medical Corporation reported FY2025 revenue of $61.9 million, a 10% increase from $56.1 mill
Mar 25, 2026
NEUTRAL
3/10
Journey Medical Corporation (DERM) announced it will release its year-end 2025 financial results on
Mar 18, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.50 mean target
+118.4% upside
Strong Buy (1.00)
$12.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $6.18 |
| Target Low | $12.00 |
| Target Mean | $13.50 |
| Target Median | $13.00 |
| Target High | $16.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.02 | $-0.07 | $0.06 | 85.9% | -12.5% | 1↑ 1↓ | $0.0B | 22.4% | 4 |
| Next Q 2026-09-30 |
$0.05 | $0.01 | $0.14 | 158.3% | -4.5% | 1↑ 1↓ | $0.0B | 27.0% | 4 |
| Current FY 2026-12-31 |
$0.07 | $-0.05 | $0.40 | 113.8% | -10.3% | — | $0.1B | 33.6% | 4 |
| Next FY 2027-12-31 |
$1.04 | $0.45 | $1.76 | 1496.1% | +2.0% | 1↑ 2↓ | $0.1B | 66.7% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.022 | |
| 7d ago | $-0.022 | |
| 30d ago | $-0.020 | -0.002 |
| 60d ago | $-0.020 | -0.002 |
| 90d ago | $0.050 | -0.073 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 19, 2026
other
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,”
May 13, 2026
earnings
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p>
May 13, 2026
earnings_calendar
DERM Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
earnings
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET <pre>Company to host confe
Apr 21, 2026
contract
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 <pre>Payer
Mar 27, 2026
short_interest
FTD: DERM — 105,365 shares ($0.5M) failed to deliver
Settlement: 20260327, Price: $4.78, FTD Value: $503,644.7, JOURNEY MED CORP COM (DE)
Mar 25, 2026
earnings
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
<p align="center"><em>Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024</em></p>
Mar 25, 2026
earnings_calendar
DERM Q4 2025 Earnings After Market Close — 2026-03-25
Mar 19, 2026
earnings_calendar
DERM Q4 2025 Earnings After Market Close — 2026-03-19
Mar 18, 2026
earnings
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET <pre>Company to host con
Mar 2, 2026
short_interest
FTD: DERM — 123,800 shares ($1.0M) failed to deliver
Settlement: 20260302, Price: $8.17, FTD Value: $1,011,446, JOURNEY MED CORP COM (DE)